A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC).
The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).
Key Inclusion Criteria:
Note: at least 85% of participants included in the study must be pretreated with anti-PD-[L]1 therapy.
Refer to protocol for country-specific requirements for participants in China.
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
GileadClinicalTrials@gilead.com1-833-445-3230 (GILEAD-0)
Muncie, Indiana 47303, United States
Owensboro, Kentucky 42303, United States
Albuquerque, New Mexico 87109, United States
Buenos Aires, C1426ANZ, Argentina
Buenos Aires, Argentina
New South Wales, New South Wales 2500, Australia
Queensland, Queensland 4006, Australia
Fortaleza Ceara, 60430-230, Brazil
Recife Pernambuco, 50070-550, Brazil
Hangzhou, 310009, China
Hangzhou, 552440, China
Wuhan, 430030, China
Wuhan, 430030, China
Bochum, 44791, Germany
Esslingen am Neckar, 73730, Germany
Athens, 11522, Greece
Larissa, 41110, Greece
Naharyia, 11111, Israel
Roma, 144, Italy
Ehime, 791-0245, Japan
Nigata-shi, 9518520, Japan
Lembah Pantai, 59100, Malaysia
Bucharest, 22328, Romania
Changwon-Si, South Korea
Seongbuk-Gu, South Korea
Barcelona, 08916, Spain
Las Palmas de Gran Canaria, 35016, Spain
Kaohsiung City, 80756, Taiwan